Early Development GMPs for Stability An Industry Perspective (Part IV)

Acken, Bruce; Alasandro, Mark; Colgan, Stephen; Curry, Paul; Diana, Frank; Li, Q. Chan; Li, Z. Jane; Mazzeo, Tony; Rignall, Andy; Tan, Z. Jessica; Timpano, Robert
October 2012
Pharmaceutical Technology Europe;Oct2012, Vol. 24 Issue 10, p61
Trade Publication
The authors, part of the International Consortium on innovation and Quality in Pharmaceutical Development (IQ Consortium), explore and define common industry approaches and practices when applying GMPs in early development. A working group of the consortium aims to develop a set of recommendations that can help the industry identify opportunities to improve lead time to first-in-human studies and reduce development costs while maintaining required quality standards and ensuring patient safety.


Related Articles

  • Quality by Design for Analytical Methods. Nethercote, Phil; Ermer, Joachim // Pharmaceutical Technology Europe;Oct2012, Vol. 24 Issue 10, p52 

    Adoption of quality-by-design (QbD) concepts in pharmaceutical development and manufacture is becoming increasingly well-established. QbD concepts are aimed at improving the robustness of manufacturing processes based upon adopting a systematic and scientific approach to development and...

  • Space-the Next Frontier. Cass, Penny L.; McLeod, Lorna D. // BioPharm International;Sep2001, Vol. 14 Issue 9, p68 

    Discusses capacity problems faced by biopharmaceutical companies. Shortage of manufacturing space; Management's reluctance to invest too soon in the high cost of designing, building, validating and qualifying a production facility; Consideration of alternative production methods; Manufacturers'...

  • Building Automation Systems in a PAT Framework. Whitney, Jonathan T.; Granger, Mark A. // BioPharm International;Sep2005, Vol. 18 Issue 9, p70 

    Reports on the role of building automation technology system in maintaining and validating quality manufacturing environments in the U.S. Provision of closed-loop feedback control and analysis of the process of manufacturing a quality environment with optimum temperature; Details on the...

  • Risk-Based Cleaning Validation in Biopharmaceutical API Manufacturing. Mollah, A. Hamid; White, Edward K. // BioPharm International;Nov2005, Vol. 18 Issue 11, p54 

    The article addresses issues related to cleaning validation in biopharmaceutical active pharmaceutical ingredients (APIs). The factors that cause difficulties in proteinaceous residue or polysaccharide removal are also discussed in the article. Emphasis was given by the author to the risk-based...

  • Novartis increase Swiss production.  // European Pharmaceutical Executive;Oct2007, p9 

    The article reports that Novartis AG is planning to spend about $249.8 million to expand production capacity at its plant in Schweizerhalle, Switzerland. The plan of the company is to help meet demand for its hypertension treatments Diovan, Exforge, and Rasilez. Information about the economic...

  • Advances in Pharmaceutical Process Analysers. Anderson, David // Pharmaceutical Technology Europe;Aug2005, Vol. 17 Issue 8, p25 

    The article discusses advances in process analytical devices and how they can be applied to both new and existing pharmaceutical facilities. Compared to the past, analytical transmitter analogue outputs and alarm relays nowadays, have to be wired at the transmitter, then the wires need to be...

  • Online Nanoparticle Sizing Technology: A New PAT for Pharma Manufacturing. Vaisman, Alon // Pharmaceutical Processing;Oct2015, Vol. 30 Issue 8, p26 

    The article highlights the Dynamic Light Scattering (DLS) technique as a parameter for pharmaceutical manufacturing. Topics discussed include how online DLS system works, the benefits it provides in the whole manufacturing process, and its use in the production monitoring services. Illustrations...

  • Progress in the prediction of protein aggregation. Challener, Cynthia A. // BioPharm International;Jan2014, Vol. 27 Issue 1, p28 

    The article discusses progress in the prediction of aggregation manufacturing, downstream processing, formulation, storage, shipping, and administration of protein-based drugs. Particular focus is given to techniques in enabling the design and formulation of stable, protein-based therapeutics....

  • Parenteral Possibilities. Auerbach, Mike // Pharmaceutical Processing;Sep2013, Vol. 28 Issue 7, p38 

    The article discusses the expansion of biopharmaceutical market which coincides with the need for parenteral manufacturing services. It states that much attention has been given to the promise of biopharmaceuticals as the pharmaceutical industry seeks for new products. It says that more...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics